A Study of the Pharmacokinetics of Testosterone Metered Dose (MD)-Lotion Formulations

• Status: Completed
• Trial end date: 2008-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

Testosterone replacement treatment is the most effective way of treating hypogonadism in men. Acrux has a propriety testosterone replacement product, Testosterone MD-Lotion and this study will evaluate pharmacokinetics of testosterone MD-Lotion formulations.The study will also assess safety of the product.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Methyltestosterone; Testosterone; Testosterone 17 beta-cypionate; Testosterone enanthate; Testosterone undecanoate

Criteria

Inclusion Criteria:

• Male study participants with a prior documented diagnosis of hypoandrogenism as evidenced by previously documented: Hypothalamic, pituitary or testicular disorder or a Serum testosterone less than or equal to 300 ng/dL

• Were receiving, or in the investigator's opinion were eligible to receive treatment for hypoandrogenism

• Body Mass Index (BMI) less than 35 kg/m^2

• Passed the required laboratory and physical screening tests

• Haemoglobin levels at screening greater than or equal to 13.0 g/dL

• Adequate venous access on left or right arm

• Able to communicate with study staff, understand the study information sheet and sign the written Informed Consent forms; willing to follow and comply with study procedures

Exclusion Criteria:

• Any significant history of allergy and/or sensitivity to the drug products or their excipients, including any history of sensitivity to testosterone and/or sunscreens

• Any clinically significant chronic illness or finding on screening physical exam and/or laboratory testing

• Chronic skin disorder (e.g. eczema, psoriasis) likely to interfere with transdermal drug absorption

• Men with suspected reversible hypoandrogenism (i.e. due to medications, stress)

• Any man in whom testosterone therapy is contraindicated, which included those with:

• Known or suspected carcinoma (or history of carcinoma) of the prostate or symptoms of benign prostatic hyperplasia and/or symptoms of lower urinary obstruction,

• Known or suspected carcinoma (or history of carcinoma) of the breast,

• Severe liver damage i.e. cirrhosis, hepatitis or liver tumours,

• Active deep vein thrombosis, thromboembolic disorders or a documented history of these conditions,

• Significant cerebrovascular or coronary artery disease,

• Known or suspected sleep apnoea,

• Hematocrit > 51%

• Men with clinically significant prostate exam or clinically significant elevated serum prostate specific antigen (PSA) level, or age adjusted reference range of PSA values.

• Current history of drug or alcohol abuse (more than 4 standard drinks per day and/or abnormal liver function tests 3 times the upper limit of the normal range values)

• Men taking concomitant medications that affect sex hormone binding globulin (SHBG) or testosterone concentrations or metabolism, or that were cytochrome P450 inducers or inhibitors, anti-coagulants (warfarin), or diabetic medications (insulin), anti-histamines

• Men involved in sport in which there was screening for anabolic steroids

• Men with uncontrolled diabetes (hemoglobin A1c [HbA1c] greater than or equal to 10%)

• Men taking any Investigational Product, or who had received an Investigational Product within 28 days prior to screening or 5 half-lives (whichever was the longer)

• Any contraindication to blood sampling

• Study participants who planned to have a surgical procedure during the course of the study

• Study participants with a partner of child bearing potential who was not willing to use adequate contraception (i.e. condoms) for the duration of the study

• Study participants whose partners were pregnant